Khaldoun Almhanna, MD, MPH

Where You Are:

Khaldoun Almhanna, MD, MPH

Medical Oncology


          •  Medical Oncology

          •  Cleveland Clinic - Hematology-Oncology

          •  Oakwood Hospital and Medical Center - Internal Medicine

          •  Damascus University - MD

  • Almhanna K, Hoffe S. Esophageal cancer 2015, more questions than answers. J Gastrointest Oncol. 2015 Feb;6(1):1-2. Pubmedid: 25642332. Pmcid: PMC4294825.

  • Ajani JA, D'Amico TA, Almhanna K, Bentrem DJ, Besh S, Chao J, Das P, Denlinger C, Fanta P, Fuchs CS, Gerdes H, Glasgow RE, Hayman JA, Hochwald S, Hofstetter WL, Ilson DH, Jaroszewski D, Jasperson K, Keswani RN, Kleinberg LR, Korn WM, Leong S, Lockhart AC, Mulcahy MF, Orringer MB, Posey JA, Poultsides GA, Sasson AR, Scott WJ, Strong VE, Varghese TK, Washington MK, Willett CG, Wright CD, Zelman D, McMillian N, Sundar H. Esophageal and esophagogastric junction cancers, version 1.2015. J Natl Compr Canc Ne. 2015 Feb;13(2):194-227. Pubmedid: 25691612.

  • Kothari N, Almhanna K. Current status of novel agents in advanced gastroesophageal adenocarcinoma. J Gastrointest Oncol. 2015 Feb;6(1):60-74. Pubmedid: 25642339. Pmcid: PMC4294823.

  • Abbott AM, Kim R, Hoffe SE, Arslan B, Biebel B, Choi J, El-Haddad G, Kis B, Sweeney J, Meredith KL, Almhanna K, Strosberg J, Shibata D, Fulp WJ, Shridhar R. Outcomes of Therasphere Radioembolization for Colorectal Metastases. Clin Colorectal Cancer. 2015 Feb. Pubmedid: 25795047.

  • Almhanna K, Hoffe S, Strosberg J, Dinwoodie W, Meredith K, Shridhar R. Concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil (5-FU) and cisplatin for locally advanced resectable esophageal cancer. J Gastrointest Oncol. 2015 Feb;6(1):39-44. Pubmedid: 25642336. Pmcid: PMC4294830.

  • Abbott A, Shridhar R, Hoffe S, Almhanna K, Doepker M, Saeed N, Meredith K. Robotic assisted Ivor Lewis esophagectomy in the elderly patient. J Gastrointest Oncol. 2015 Feb;6(1):31-38. Pubmedid: 25642335. Pmcid: PMC4294822.

  • Shridhar R, Freilich J, Hoffe SE, Almhanna K, Fulp WJ, Yue B, Karl RC, Meredith K. Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus. Ann Surg Oncol. 2014 Nov;21(12):3744-3750. Pubmedid: 24854492.

  • Brana I, Berger R, Golan T, Haluska P, Edenfield J, Fiorica J, Stephenson J, Martin LP, Westin S, Hanjani P, Jones MB, Almhanna K, Wenham RM, Sullivan DM, Dalton WS, Gunchenko A, Cheng JD, Siu LL, Gray JE. A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours. Brit J Cancer. 2014 Nov;111(10):1932-1944. Pubmedid: 25290091. Pmcid: PMC4229637.

  • Wong J, Rahman S, Saeed N, Lin HY, Almhanna K, Shridhar R, Hoffe S, Meredith KL. Effect of Body Mass Index in Patients Undergoing Resection for Gastric Cancer: A Single Center US Experience. J Gastrointest Surg. 2014 Mar;18(3):505-511. Pubmedid: 24443204.

  • Wong J, Rahman S, Saeed N, Lin HY, Almhanna K, Shridhar R, Hoffe S, Meredith KL. Prognostic impact of lymph node retrieval and ratio in gastric cancer: a u.s. Single center experience. J Gastrointest Surg. 2013 Dec;17(12):2059-2066. Pubmedid: 24129828.

  • Almhanna K, Cubitt CL, Zhang S, Kazim S, Husain K, Sullivan D, Sebti S, Malafa M. MK-2206, an Akt inhibitor, enhances carboplatinum/paclitaxel efficacy in gastric cancer cell lines. Cancer Biol Ther. 2013 Oct;14(10):932-936. Pubmedid: 23917345. Pmcid: PMC3926890.

  • Shridhar R, Hoffe SE, Almhanna K, Weber JM, Chuong MD, Karl RC, Meredith K. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy. Ann Surg Oncol. 2013 Sep;20(9):3038-3043. Pubmedid: 23625142.

  • Pimiento JM, Weber J, Hoffe SE, Shridhar R, Almhanna K, Vignesh S, Karl RC, Meredith KL. Outcomes associated with surgery for T4 esophageal cancer. Ann Surg Oncol. 2013 Aug;20(8):2706-2712. Pubmedid: 23504118.

  • Wong J, Weber J, Almhanna K, Hoffe S, Shridhar R, Karl R, Meredith KL. Extent of lymphadenectomy does not predict survival in patients treated with primary esophagectomy. J Gastrointest Surg. 2013 Jul;17(9):1562-1569. Pubmedid: 23818125.

  • Shridhar R, Almhanna K, Hoffe SE, Fulp W, Weber J, Chuong MD, Meredith KL. Increased survival associated with surgery and radiation therapy in metastatic gastric cancer: a Surveillance, Epidemiology, and End Results database analysis. Cancer. 2013 Jun;119(9):1636-1642. Pubmedid: 23361968.

  • Shridhar R, Weber J, Hoffe SE, Almhanna K, Karl R, Meredith K. Adjuvant Radiation Therapy and Lymphadenectomy in Esophageal Cancer: A SEER Database Analysis. J Gastrointest Surg. 2013 Jun;17(8):1339-1345. Pubmedid: 23749498.

  • Hernandez JM, Dimou F, Weber J, Almhanna K, Hoffe S, Shridhar R, Karl R, Meredith K. Defining the Learning Curve for Robotic-assisted Esophagogastrectomy. J Gastrointest Surg. 2013 May;17(8):1346-1351. Pubmedid: 23690208.

  • Melis M, Weber J, Shridhar R, Hoffe S, Almhanna K, Karl RC, Meredith KL. Body mass index and perioperative complications after oesophagectomy for adenocarcinoma: a systematic database review. BMJ Open. 2013 May;3(5). Pubmedid: 23645908. Pmcid: PMC3646172.

  • Strosberg J, Weber J, Feldman M, Goldman J, Almhanna K, Kvols L. Above-Label Doses of Octreotide-LAR in Patients With Metastatic Small Intestinal Carcinoid Tumors. Gastrointest Cancer Res. 2013 May;6(3):81-85. Pubmedid: 23936548. Pmcid: PMC3737510.

  • Almhanna K, Meredith KL, Hoffe SE, Shridhar R, Coppola D. Targeting the human epidermal growth factor receptor 2 in esophageal cancer. Cancer Control. 2013 Apr;20(2):111-116. Pubmedid: 23571701.

  • Almhanna K, Shridhar R, Meredith KL. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: is there a standard of care?. Cancer Control. 2013 Apr;20(2):89-96. Pubmedid: 23571699.

  • Vignesh S, Hoffe SE, Meredith KL, Shridhar R, Almhanna K, Gupta AK. Endoscopic Therapy of Neoplasia Related to Barrett's Esophagus and Endoscopic Palliation of Esophageal Cancer. Cancer Control. 2013 Apr;20(2):117-129. Pubmedid: 23571702.

  • Wong JY, Shridhar R, Almhanna K, Hoffe SE, Karl RC, Meredith KL. The impact of body mass index on esophageal cancer. Cancer Control. 2013 Apr;20(2):138-143. Pubmedid: 23571704.

  • Shridhar R, Almhanna K, Meredith KL, Biagioli MC, Chuong MD, Cruz A, Hoffe SE. Radiation therapy and esophageal cancer. Cancer Control. 2013 Apr;20(2):97-110. Pubmedid: 23571700.

  • Chuong MD, Freilich JM, Hoffe SE, Fulp W, Weber JM, Almhanna K, Dinwoodie W, Rao N, Meredith KL, Shridhar R. Intensity-Modulated Radiation Therapy vs. 3D Conformal Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal. Gastrointest Cancer Res. 2013 Mar;6(2):39-45. Pubmedid: 23745158. Pmcid: PMC3674462.

  • Almhanna K, Strosberg JR. Multimodality approach for locally advanced esophageal cancer. World J Gastroenterol. 2012 Oct;18(40):5679-5687. Pubmedid: 23155307. Pmcid: PMC3484335.

  • Almhanna K, El-Rayes B, Sethi S, Dyson G, Heilbrun L, Philip PA, Sarkar F. Association between COX-2 expression and effectiveness of COX-2 inhibitors in a phase II trial in patients with metastatic colorectal adenocarcinoma. Anticancer Res. 2012 Aug;32(8):3559-3563. Pubmedid: 22843946. Pmcid: PMC3807874.

  • Shridhar R, Hayman T, Hoffe SE, Weber J, Almhanna K, Chuong M, Karl RC, Meredith KL. Body mass index and survival in esophageal adenocarcinoma treated with chemoradiotherapy followed by esophagectomy. J Gastrointest Surg. 2012 Jul;16(7):1296-1302. Pubmedid: 22399271.

  • Strosberg JR, Yeatman T, Weber J, Coppola D, Schell MJ, Han G, Almhanna K, Kim R, Valone T, Jump H, Sullivan D. A phase II study of RO4929097 in metastatic colorectal cancer. Eur J Cancer. 2012 May;48(7):997-1003. Pubmedid: 22445247.

  • Dittrick GW, Weber JM, Shridhar R, Hoffe S, Melis M, Almhanna K, Barthel J, McLoughlin J, Karl RC, Meredith KL. Pathologic Nonresponders after Neoadjuvant Chemoradiation for Esophageal Cancer Demonstrate no Survival Benefit Compared with Patients Treated with Primary Esophagectomy. Ann Surg Oncol. 2012 May;19(5):1678-1684. Pubmedid: 22045465.

  • Almhanna K. Targeted therapy for gastric adenocarcinoma. Adv Pharmacol. 2012;65:437-470. Pubmedid: 22959034.

  • Almhanna K, Strosberg J, Malafa M. Targeting AKT protein kinase in gastric cancer. Anticancer Res. 2011 Dec;31(12):4387-4392. Pubmedid: 22199303.

  • Almhanna K, Philip PA. Safety and efficacy of sorafenib in the treatment of hepatocellular carcinoma. Onco Targets Ther. 2011 Jul;2:261-267. Pubmedid: 20616913. Pmcid: PMC2886319.

  • Ali S, Almhanna K, Chen W, Philip PA, Sarkar FH. Differentially expressed miRNAs in the plasma may provide a molecular signature for aggressive pancreatic cancer. Am J Transl Res. 2011 Jul;3(1):28-47. Pubmedid: 21139804. Pmcid: PMC2981424.

  • Almhanna K, Philip PA. Defining new paradigms for the treatment of pancreatic cancer. Curr Treat Options Oncol. 2011 Jun;12(2):111-125. Pubmedid: 21461670.

  • El-Rayes BF, Jasti P, Severson RK, Almhanna K, Philip PA, Shields A, Zalupski M, Heilbrun LK. Impact of race, age, and socioeconomic status on participation in pancreatic cancer clinical trials. Pancreas. 2010 Oct;39(7):967-971. Pubmedid: 20467351.

  • Kim R, Tsao R, Tan A, Byrne M, Almhanna K, Lazaryan A, Elson P, Pelley RJ. A single institution review of adjuvant therapy outcomes for resectable pancreatic adenocarcinoma: outcome and prognostic indicators. J Gastrointest Surg. 2010 Jul;14(7):1159-1169. Pubmedid: 20446118.

  • Azmi AS, Philip PA, Almhanna K, Beck FW, Sarkar FH, Mohammad RM. MDM2 inhibitors for pancreatic cancer therapy. Mini Rev Med Chem. 2010 Jun;10(6):518-526. Pubmedid: 20377522.

  • Almhanna K, Wongchaowart N, Sweetenham J. Intracerebral Hodgkin's lymphoma in a patient with chronic lymphocytic leukemia/small lymphocytic lymphoma: a case report and literature review. Cancer Invest. 2009 Feb;27(2):215-220. Pubmedid: 19235595.

  • Almhanna K, Kim R. Second-line therapy for gemcitabine-refractory pancreatic cancer: is there a standard?. Oncology (Williston Park). 2008 Sep;22(10):1176-1183. Pubmedid: 18935928.

  • Almhanna K, Pelley RJ, Thomas Budd G, Davidson J, Moore HC. Subcutaneous implantable venous access device erosion through the skin in patients treated with anti-vascular endothelial growth factor therapy: a case series. Anticancer Drugs. 2008 Feb;19(2):217-219. Pubmedid: 18176119.

  • Saif MW, Hashmi S, Zelterman D, Almhanna K, Kim R. Capecitabine vs continuous infusion 5-FU in neoadjuvant treatment of rectal cancer. A retrospective review. Int J Colorectal Dis. 2008 Feb;23(2):139-145. Pubmedid: 17909820.

  • Almhanna K, Kalmadi S, Pelley R, Kim R. Neoadjuvant therapy for hepatocellular carcinoma: is there an optimal approach?. Oncology (Williston Park). 2007 Aug;21(9):1116-1122. Pubmedid: 17910314.

  • Almhanna K, Khan P, Schaldenbrand M, Momin F. Sideroblastic anemia after bariatric surgery. Am J Hematol. 2006 Feb;81(2):155-156. Pubmedid: 16432847.

  • Chavez JC, Almhanna K, Berti-Mattera LN. Transient expression of hypoxia-inducible factor-1 alpha and target genes in peripheral nerves from diabetic rats. Neurosci Lett. 2005 Feb;374(3):179-182. Pubmedid: 15663958.

  • Almhanna K, Palanichamy N, Sharma M, Hobbs R, Sil A. Unilateral brachial plexopathy associated with West Nile virus meningoencephalitis. Clin Infect Dis. 2003 Jun;36(12):1629-1630. Pubmedid: 12802774.

  • Almhanna K, Wilkins PL, Bavis JR, Harwalkar S, Berti-Mattera LN. Hyperglycemia triggers abnormal signaling and proliferative responses in Schwann cells. Neurochem Res. 2002 Nov;27(11):1341-1347. Pubmedid: 12512939.

  • Berti-Mattera LN, Harwalkar S, Hughes B, Wilkins PL, Almhanna K. Proliferative and morphological effects of endothelins in Schwann cells: roles of p38 mitogen-activated protein kinase and Ca(2+)-independent phospholipase A2. J Neurochem. 2001 Dec;79(6):1136-1148. Pubmedid: 11752055.

  • Berti-Mattera LN, Wilkins PL, Harwalkar S, Madhun Z, Almhanna K, Mattera R. Endothelins regulate arachidonic acid release and mitogen-activated protein kinase activity in Schwann cells. J Neurochem. 2000 Dec;75(6):2316-2326. Pubmedid: 11080183.

Dr. Khaldoun Almhanna is a medical oncologist of the Department of Gastrointestinal Oncology at Moffitt Cancer Center.  He is an assistant professor of oncology at the University of South Florida College of Medicine

Dr. Almhanna’s research and clinical interests include phase I and II trials using personalized targeted therapy for gastrointestinal cancers, in particular, esophageal and gastric cancer.

Dr. Almhanna received his medical degree from Damascus University School of Medicine in Syria and served an internal medicine internship at Damascus University Hospital.  He went on to receive a master’s of public health degree from Case Western Reserve University in Cleveland, OH, followed by an internal medicine residency at Oakwood Hospital and Medical Center in Dearborn, MI.  Dr. Almhanna completed a hematology/oncology fellowship at the Cleveland Clinic.

Before coming to Moffitt in 2010, Dr. Almhanna was an assistant professor of oncology at Wayne University in Detroit, MI.  He is widely published and serves as an editorial reviewer for Clinical Colorectal Cancer, Head and Neck Cancer and Disease of the Esophagus.  Dr. Almhanna is a member of the American Society of Hematology and American Society of Clinical Oncology.

Dr. Almhanna was voted Doctor of the Year in Michigan in 2009 and Doctor of the Year in Tampa in 2011.  He is fluent in English, Arabic and French.


TOOLS:   Font Size small font resizer separator font resizer separator big font resizer
 |  Site Map  |  Privacy Policy  |  Terms and Conditions